U.S. HEALTH AGENCIES LIFT PAUSE ON JOHNSON & JOHNSON'S COVID-19 VACCINE AFTER SAFETY REVIEW

Highlights

• This review included two meetings of the CDC's Advisory Committee on Immunization Practices, the US Food and Drug Administration and the US Centers for Disease Control and Prevention

• According to the FDA, the available data showcases that the vaccine's known and potential benefits clearly outweigh its known and potential risks in individuals ageing 18 or more

Following a detailed s....